Armed Forces Institute of Pathology

Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, December 6, 2022

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.

Key Points: 
  • Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.
  • Before joining Verge, Dr. Cadavid served as Chief Medical Officer of X4 Pharmaceuticals where he led the clinical development of mavorixafor and recently delivered positive phase 3 data.
  • His work included the rapid advance of losmapimod from target identification to proof of concept in Facioscapulohumeral Muscular Dystrophy (FSHD).
  • What stands out to me most, though, is his knack using disruptive innovation to enable disciplined execution, said Alice Zhang, CEO and co-founder of Verge Genomics.

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

Retrieved on: 
Thursday, September 29, 2022

Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics.

Key Points: 
  • Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics.
  • ngTMA supports research collaborators with an interdisciplinary approach to studying tumor biology and disease states.
  • We are thrilled to be partnering with ngTMA to jointly empower biopharma customers with tissue multiplex services.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

Retrieved on: 
Monday, September 5, 2022

SAN DIEGO, Sept. 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the upcoming presentation of multiple oncology research abstracts at this year's European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and Illumina's oncology assays for cancer research and patient care. 

Key Points: 
  • The abstractsunderscore the value of next-generation sequencing (NGS) and Illumina's oncology assays for cancer research and patient care.
  • "There is growing evidence that using comprehensive genomic profiling that includes pan-cancer and immunotherapy biomarkers can identify the greatest number of patients who most benefit from targeted therapy."
  • HRD status has emerged as an important biomarker in tumors that have high levels of DNA damage, such as ovarian cancer.
  • However, to enable genomic profiling of ovarian cancer tumors with indications for PARP inhibitors and predict response to these treatments, labs must reliably assess HRD status in those tumors.

Five leading children’s hospitals secure $29M in federal funding to enhance future pandemic readiness

Retrieved on: 
Tuesday, July 19, 2022

, principal investigator of this grant and division chief of Emergency Medicine and medical director of Emergency Preparedness at Childrens National.

Key Points: 
  • , principal investigator of this grant and division chief of Emergency Medicine and medical director of Emergency Preparedness at Childrens National.
  • In September 2021, HRSA launched the Regional PPN by funding five pediatric hospitals to support the planning and preparation of childrens hospitals to respond to a global health threat.
  • Childrens National is home to the Childrens National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation .
  • As a non-profit, Children's National Hospital relies on generous donors to help ensure that every child receives the care they need.

Northern Ireland goes live with pathology solution from Sectra--joins together radiology and pathology images

Retrieved on: 
Tuesday, February 22, 2022

LINKPING, Sweden, Feb. 22, 2022 /PRNewswire/ -- Northern Ireland becomes the first UK region to combine pathology and radiology images and reports in the same medical imaging system.

Key Points: 
  • LINKPING, Sweden, Feb. 22, 2022 /PRNewswire/ -- Northern Ireland becomes the first UK region to combine pathology and radiology images and reports in the same medical imaging system.
  • With our digital pathology system we will be ready to embrace that in Northern Ireland."
  • Nicky Harvey, NIPACS programme manager for Business Services Organisation said: "Digital pathology is a huge transformation for Northern Ireland.
  • The success of the digital pathology project has also received great support from Clinical professionals in Northern Ireland.

Northern Ireland goes live with pathology solution from Sectra--joins together radiology and pathology images

Retrieved on: 
Tuesday, February 22, 2022

LINKPING, Sweden, Feb. 22, 2022 /PRNewswire/ -- Northern Ireland becomes the first UK region to combine pathology and radiology images and reports in the same medical imaging system.

Key Points: 
  • LINKPING, Sweden, Feb. 22, 2022 /PRNewswire/ -- Northern Ireland becomes the first UK region to combine pathology and radiology images and reports in the same medical imaging system.
  • With our digital pathology system we will be ready to embrace that in Northern Ireland."
  • Nicky Harvey, NIPACS programme manager for Business Services Organisation said: "Digital pathology is a huge transformation for Northern Ireland.
  • The success of the digital pathology project has also received great support from Clinical professionals in Northern Ireland.

National Institutes of Health awards Children’s National Hospital $6.7M to build out additional lab space at the new Children’s National Research & Innovation Campus, preparing phase II

Retrieved on: 
Wednesday, September 22, 2021

Washington D.C., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Childrens National Hospital today announced a $6.7 million award from the National Institute of Health (NIH) for the new Childrens National Research & Innovation Campus (RIC).

Key Points: 
  • Washington D.C., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Childrens National Hospital today announced a $6.7 million award from the National Institute of Health (NIH) for the new Childrens National Research & Innovation Campus (RIC).
  • The campus began opening in early 2021 and brings together Childrens National with top-tier research and innovation partners: Johnson & Johnson Innovation - JLABS @ Washington, DC and Virginia Tech.
  • They come together with a focus on driving discoveries and innovation that will save and improve the lives of children.
  • This NIH award is the latest confirmation that we are creating something very special at the Childrens National Research & Innovation Campus, said Kurt Newman, M.D.

Summit Dermatology Joins Epiphany Dermatology

Retrieved on: 
Monday, August 23, 2021

AUSTIN, Texas, Aug. 23, 2021 /PRNewswire/ --Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in the East Texas market through its partnership with Summit Dermatology.

Key Points: 
  • AUSTIN, Texas, Aug. 23, 2021 /PRNewswire/ --Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in the East Texas market through its partnership with Summit Dermatology.
  • Jason Blaser, MD, board-certified dermatologist and dermatopathologist of Summit Dermatology, has a well-established reputation for providing high-quality dermatology services to patients in Tyler and surrounding communities in East Texas.
  • Epiphany also benefits from the clinical expertise of Dr. Blaser, as best practices are collaboratively shared across the Epiphany network.
  • Epiphany Dermatology is a rapidly expanding dermatology company, driven by a passion to improve access to high quality dermatologic care in a values-based manner.